Jul 29, 2019
Israel’s Savicell says its test measures the metabolic ‘signatures’ of immune cells circulating in the blood in response to disease.
Of all cancers, lung cancer is the deadliest, largely because it is so difficult to diagnose early on. With very few nerve endings in the lungs, this type of cancer doesn’t cause painful symptoms until a tumor has grown quite large – and by that time, it’s often too late.
“If the cancer is detected at stage 1, the survival rate is 80 percent,” explains Giora Davidovits, CEO of Israeli startup Savicell, which is developing a new blood test to diagnose lung cancer.
Read More: Israel21c
